| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Truist Securities analyst Richard Newitter reiterates Globus Medical (NYSE:GMED) with a Buy and raises the price target from...
Barclays analyst Matt Miksic maintains Globus Medical (NYSE:GMED) with a Overweight and raises the price target from $106 to...
Expedia, SanDisk, and Penumbra led last week's large-cap gainers, with strong earnings and raised guidance fueling broad do...
RBC Capital analyst Shagun Singh maintains Globus Medical (NYSE:GMED) with a Outperform and raises the price target from $88...
Wells Fargo analyst Vik Chopra maintains Globus Medical (NYSE:GMED) with a Overweight and raises the price target from $66 t...